Background. The Surgical Outcome Risk Tool (SORT) is a risk stratification instrument used to predict perioperative mortality. We wanted to evaluate and refine SORT for better prediction of the risk of postoperative morbidity. Methods. We analysed prospectively collected data from a single-centre cohort of adult patients undergoing major elective surgery. The data set was split randomly into derivation and validation samples. We used logistic regression to construct a model in the derivation sample to predict postoperative morbidity as defined using the validated Postoperative Morbidity Survey (POMS) assessed at 1 week after surgery. Performance of this 'SORT-morbidity' model was then tested in the validation sample and compared against the Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM). Results. The SORT-morbidity model was constructed using a derivation sample of 1056 patients and validated in a further 527 patients. SORT-morbidity was well calibrated in the validation sample, as assessed using calibration plots and the Hosmer-Lemeshow test (v 
Although there are many tools to predict or assess risk based on mortality [e.g. the Portsmouth modification of the Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (P-POSSUM) 2 and Surgical Risk Scale (SRS)], 3 there are fewer tools available to predict morbidity outcomes. This is despite morbidity being an important outcome of concern to both patients and clinicians. Firstly, morbidity after major surgery is a more common outcome than death, making it a potentially more sensitive measure by which to compare individual, team, or provider performance. 4 Secondly, morbidity can impact significantly on quality of life and long-term survival, making it an important target for quality improvement. 5 Indeed, the P-POSSUM was a variation of an earlier tool, the Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM), which was originally developed in the 1990s to address the lack of tools for predicting morbidity outcomes at the time. 1 6 POSSUM remains one of the most frequently used tools for predicting morbidity risk. The Surgical Outcome Risk Tool (SORT) was developed after the 2011 National Confidential Enquiry into Patient Outcome and Death (NCEPOD) report Knowing the Risk, to enable better identification of patients at high risk of postoperative morbidity and mortality, clearer documentation of risks, and better discussions about risks with patients before surgery. 7 8 SORT is a parsimonious model using six routinely collected data items, designed to predict, before surgery, an individual's probability of 30 day mortality. It compared favourably with other previously validated risk stratification tools, namely the ASA physical status (ASA PS) grade and SRS, and has been externally validated recently in a cohort of patients undergoing hip fracture surgery. 9 Therefore, the aims of our study were to develop and validate a new model to predict the likelihood of postoperative morbidity using predictor variables found in SORT, and then compare its performance against POSSUM.
Methods

Patient population
Data were prospectively collected from 1934 consecutive adult patients who had undergone a variety of elective major inpatient operations at University College London Hospital between June 2009 and May 2012. Ethics approval was not required because the routine collection of these data was approved as service evaluation by the local research and development office.
Patient characteristic and perioperative data collection was conducted by trained research staff, independent of the clinical care teams treating the patients. Risk variable, co-morbidity, hospital length of stay (LOS), and mortality data were obtained from patient notes or electronic record review. POMS outcomes were measured by research staff visiting the patients at the bedside and reviewing patient notes. Baseline co-morbidities were recorded for each patient and, as with the original development and validation of SORT, free-text surgical procedure descriptions were categorized by surgical specialty and by surgical severity, based on the reference manual for AXA PPP Healthcare Specialist Procedure Codes (examples of AXA PPP procedure coding for surgical severity can be found in Supplementary material Table S1 ). 7 10 Postoperative Morbidity Survey as the morbidity outcome
The POMS was prospectively administered to patients in the cohort who remained in hospital at the following six time points: postoperative day 3, 5, 7 or 8, 14 or 15, 21, and 28 . POMS values at the 1 and 2 week time points were pragmatically allowed to be recorded at either day 7 or 8, and either day 14 or 15, respectively, in order to reduce the administrative burden placed on research staff.
POMS is an 18-item survey of short-term postoperative morbidity encompassing nine organ-system domains (Supplementary material Table S2 ) and has been multiply validated. 5 11-13 It was developed to identify morbidity of the nature that would prolong LOS; in other words, patients were unlikely to be able to return home if they exhibited POMS-defined morbidity.
Previous studies suggest that POMS-defined morbidity is a measure of 'true' morbidity when measured beyond postoperative day 5. 12 14 Early exploration of the data showed that the median LOS in our cohort was 6 days (Table 1) . We assumed that this LOS represented an uncomplicated postoperative course (i.e. even if patients experienced POMS-defined morbidity on days 3 or 5, this might be expected as part of the usual postoperative course for their surgery). Hence, POMS at either day 7 or 8 had face validity in this cohort for representing a postoperative course that met with complication(s). We therefore chose the presence of any POMS-defined morbidity, recorded at the third time point (postoperative day 7 or 8), as our morbidity outcome measure.
Treatment of patients for analysis
Patients with erroneously duplicated or missing data were excluded, and only patients with complete predictor variable and POMS outcome data were included for analysis. No imputation of missing data was performed. Patients who remained in hospital for longer than 7 days but did not have POMS outcomes recorded on day 7 were then excluded from the data set used to derive a new SORT model for predicting morbidity (SORT-morbidity). Patient characteristics of the excluded patients were compared with the original data set to look for differences between the groups.
Model derivation and internal validation for a new SORT-morbidity model
The data set was split randomly into two samples: a model derivation sample of approximately two-thirds of the cohort, and a validation sample consisting of the remaining one-third, similar to methods described previously. 7 Based on the six data items from the original SORT model for mortality, multivariable logistic regression models were fitted on the derivation sample, with a binary composite outcome variable of POMS-defined morbidity (i.e. if any one of the nine organ-system domains was
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• However, nearly all risk prediction models have limited diagnostic accuracy for any individual patient. positive, the patient was considered positive for POMS-defined morbidity) on postoperative day 7 or 8. Patients who were discharged before postoperative day 7 were assumed to have no POMS-defined morbidity.
The following logit formula was used for model fitting:
where R is the probability of a patient having POMS-defined morbidity 1 week after surgery, b 0 ; b 1 ; . . . ; b n are the model coefficients, and x 1 ; . . . ; x n are the predictor variables. For ease of reference, Protopapa's original SORT-mortality model takes the following form: (Table S1 ). We did not include surgical urgency in our model fitting because the patients in this cohort underwent elective procedures only.
Based on the original SORT model, sequential adjustments were manually made to the predictor variables, and new model coefficients were obtained by fitting against the model derivation sample of the cohort to obtain a number of candidate models (Supplementary material Table S3 ). Goodness of fit was then assessed between models by comparing their Akaike information criteria and Bayesian information criteria. [15] [16] [17] [18] To perform internal validation, each candidate SORTmorbidity model was then tested in the validation data set by assessing model calibration and discrimination, using calibration plots and the Hosmer-Lemeshow test for the former, and receiver operating characteristic (ROC) analysis for the latter. 1 19-22 Areas under the ROC curve (AUROCs) were calculated, and DeLong's method was applied to calculate confidence intervals (CIs A final parsimonious model (the simplest model that makes an accurate prediction with as few predictor variables as possible) was then chosen from this process. We selected our final model based on a balanced assessment of the goodness-of-fit measures (low Akaike information criteria and Bayesian information criteria values), calibration (non-significant P-value for Hosmer-Lemeshow test and visual inspection of calibration plots in the validation sample), and discrimination (high values of AUROC in the validation sample). We then compared the performance of our final model with POSSUM.
Sensitivity analyses and model recalibration for predicting alternative morbidity outcomes
We conducted a sensitivity analysis to test the performance of SORT-morbidity for predicting different outcomes, because of concerns that POMS-defined morbidity outcomes might be too sensitive. These concerns arose because of some less severe and relatively transient morbidity contained within the POMS outcome definitions, such as the presence of a urinary catheter and the use of anti-emetics.
Sensitivity analyses for regression models are typically performed by assessing the accuracy of the outcome prediction based on changes in the variability of the predictor variables. However, in this study we decided to test the accuracy of our model's outcome prediction if the definition used for outcome changed, in order to give the reader an understanding of the limitations of our model. This was done by assessing the calibration and discrimination of SORT-morbidity for predicting: (i) a modified POMS outcome in our patient cohort with lowerand higher-grade morbidity; and (ii) POMS outcomes at time points beyond 1 week after surgery.
For the first step, we mapped the individual POMS organsystem sub-domain items against Clavien-Dindo definitions of postoperative complications, 23 24 and assigned Clavien-Dindo grades to each POMS sub-domain. This process yielded a list of transient, low-grade POMS morbidity (equivalent to ClavienDindo Grade 1), which comprise the following: the presence of a urinary catheter (renal); presence of a fever (infectious); inability to tolerate oral diet (gastrointestinal); vomiting and abdominal distension (gastrointestinal); and pain requiring opioid analgesia (pain). All other POMS-defined morbidity sub-domains were considered high grade (Clavien-Dindo Grade 2 or more). There was a consensus among the authors as to what were considered low-grade and high-grade POMS outcomes. We then assessed SORT-morbidity performance in predicting the modified lowgrade and high-grade POMS outcomes. Details of how the POMS organ-system sub-domains were mapped against ClavienDindo grades can be found in the Supplementary material (Table S4) .
For the second step, we assessed SORT-morbidity performance in predicting more delayed POMS-defined morbidity on day 14 or 15, 21, and 28.
Lastly, using methods described by Harrell, 25 we obtained estimates of uniform linear shrinkage factors for miscalibrations identified in steps (i) and (ii) by fitting the following logit formula:
where PðYÞ is the probability of the modified outcomes either of low-or high-grade POMS, or POMS outcomes at later time points, logitðpÞ is the SORT-morbidity formula as derived earlier, a is the recalibrated intercept, and b is the recalibrated slope.
By applying the shrinkage factors, calibration would then be improved, and the accuracy of SORT-morbidity for predicting these other outcomes would also be improved. The linear shrinkage factors estimated by this method can then be applied directly onto the SORT-morbidity equation uniformly to modify all the coefficients, b 0 ; b 1 ; . . . ; b n . This technique therefore accomplishes two objectives in our study: firstly, the shrinkage factors quantify the degree to which SORT-morbidity is miscalibrated when predicting other outcomes of different severity; and secondly, the shrinkage factors can then be used for adjustments to the SORT-morbidity equation to arrive at a better accuracy for predicting these other outcomes.
Statistical analysis
Statistical analyses were performed using R version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria), with the following external packages enabled: caret, PredictABEL, pROC, and rms. For normally distributed data, means and SDs are reported. For non-normally distributed data, medians and interquartile ranges (IQRs) are reported. A P-value of 0.05 was considered statistically significant. Logistic regression models were fitted using the glm function, and shrinkage factors were estimated using the val.prob function from the rms package in R.
Results
Baseline patient characteristics and outcomes
After exclusions, 1583 patients were used to perform model derivation and internal validation for morbidity prediction. Figure 1 shows the numbers of patients excluded from the study at each stage of analysis. Baseline patient characteristics of the study cohort and patients excluded from model derivation and validation are summarized in Table 1 . The median age of the study patients was 62.6 yr, with a range of 17-95.4 yr. The majority of patients (58%) were female. The majority of the patients in the study sample underwent orthopaedic procedures (n¼873, 45%), with a substantial proportion undergoing abdominal (either colorectal or upper gastrointestinal) procedures (n¼885, 39%). Mortality in this patient sample was low, with only six deaths within 30 days of surgery recorded (0.31%). The median LOS was 6 days (IQR: 4-10). Compared with the total patient cohort, patients with missing data had a higher age, longer average LOS, and a different distribution of ASA PS grades. Table 2 shows the proportion of patients with POMS-defined morbidity at each time point when POMS was administered, as a percentage of the total patient cohort.
Model derivation and internal validation for a new SORT-morbidity model
After randomly splitting the patient cohort, multivariable logistic regression models were fitted with predictor variables based on the original SORT model data categories in a derivation sample of 1056 patients, with the outcome variable set as the presence of POMS-defined morbidity on postoperative day 7 or 8.
The coefficients for the final SORT-morbidity model are summarized in Total patients used for refitting SORT model for morbidity outcome, n=1583
Derivation sample, n=1056
Validation sample, n=527 ( Table S3 ), along with their corresponding performance statistics. Details of the Hosmer-Lemeshow tests and the tables of predicted and observed morbidity outcomes by risk quantile for SORT-morbidity and POSSUM are also included in the Supplementary material.
The new SORT-morbidity model demonstrated good calibration in the validation sample (n¼527), as shown by the calibration plot ( Fig. 2A) Fig. 2B ). SORT-morbidity compared favourably with POSSUM, which showed poorer calibration (Hosmer-Lemeshow v 2 ¼34.45, P<0.001; Fig. 2 ) and poor discrimination (AUROC¼0.66, 95% CI 0.60-0.71). However, DeLong's test for two correlated ROC curves did not show a statistically significant difference in discrimination between SORT-morbidity and POSSUM (z¼1.85, P¼0.06). These findings suggest that SORT-morbidity is as accurate as POSSUM for predicting POMS-defined morbidity at 1 week after surgery.
Sensitivity analyses and model recalibration for predicting alternative morbidity outcomes
In assessing the performance of SORT-morbidity for modified POMS outcomes, our model showed poor calibration (HosmerLemeshow test results for both were statistically significant, both P<0.01) and acceptable discrimination for predicting both low-grade and high-grade POMS morbidity (AUROC¼0.75, 95% CI: 0.72-0.78; and AUROC¼0.72, 95% CI: 0.69-0.76, respectively).
Similar to our findings for predicting high-grade POMS morbidity, SORT-morbidity was good to acceptable at discrimination, but poorly calibrated for day 14 or 15, 21, and 28 POMS outcomes (Fig. 3) . The AUROC for these outcomes ranged from 0.73 for day 14 or 15 morbidity to 0.81 for day 28 morbidity.
We estimated linear shrinkage factors to be applied to the SORT-morbidity model in order to improve its accuracy when predicting low-and high-grade POMS morbidity, and morbidity at alternative time points. Table 4 shows the recalibration intercepts, a, and slopes, b, that can be applied to the SORT-morbidity formula, and the corresponding AUROCs for the recalibrated formulae.
Discussion
Principal findings
We have developed and internally validated the SORTmorbidity model, a new refitted multivariable logistic regression model using the original SORT data items as predictors for POMS-defined morbidity 1 week after surgery. Our new model compares favourably with POSSUM and can be used in conjunction with the original SORT mortality model to inform clinical decisions and the consent process in major surgery.
Additionally, we have estimated linear shrinkage factors that can be applied to SORT-morbidity to improve its prediction for a range of other morbidity outcomes, including higher grades of morbidity and POMS-defined morbidity at later time points. With the application of these shrinkage factors, SORT-morbidity is therefore able to predict a range of different morbidity outcomes with acceptable discrimination.
Strengths and limitations of the study
In this study, we demonstrate that the performance of the new SORT-morbidity model is at least comparable with POSSUM, which is currently one of the most widely used risk prediction models for morbidity.
1 SORT-morbidity requires substantially fewer predictor variables than POSSUM, making it easier to use in routine clinical practice. Furthermore, we rigorously test the prediction performance of SORT-morbidity against a number of different morbidity outcome definitions and we estimate shrinkage factors that can be applied to the model to improve its performance for predicting these alternative outcomes.
The biggest limitation of our study is that it was conducted in a single-centre cohort of patients undergoing elective surgery that had only six (0.31%) deaths within 30 days of surgery. This is a low-mortality cohort compared with the 0.36-0.67% 30 day mortality for elective surgical cohorts reported elsewhere in the literature. 8 26 27 We were therefore unable to perform an external validation of SORT for the prediction of 30 day mortality. Our cohort exhibited some missing data, in both predictor and outcome variables. We opted for complete-patient analysis instead of imputation of missing data. We considered the number patients with missing predictor variables to be small; no single predictor variable had more than 5% of data missing. Examination of the missing data suggested that missing data did not fulfil the 'missing completely at random' (MCAR) or 'missing at random' (MAR) assumptions that are required for imputation. The variable with the largest amount of missing data was the POMS outcome variable (Fig. 1) . We suspected that the mechanism underlying the degree of missingness in our data was related to how unwell the patients were, thus making the data likely to be 'missing not at random' (MNAR). The evidence for this was that patients with missing data appeared to be older, had higher ASA PS grades, and had longer LOS (Table 1) . Imputation in such circumstances potentially leads to misleading results and may increase the bias in statistical estimates.
Defining morbidity according to POMS
We chose to define morbidity using POMS at 1 week after surgery in our analysis. The strengths and weaknesses of POMS therefore merit discussion.
There is currently no consensus on the best way to measure postoperative morbidity and surgical complications. 28 29 In their seminal paper describing the development of POSSUM, Copeland and colleagues 6 defined morbidity as any recorded occurrence of a list of complications appearing within 6 weeks of follow-up after surgery. When reporting their development of P-POSSUM, Prytherch and colleagues 2 cited difficulties about defining morbidity and uncertainty about accuracy in recording complications as the reasons for not including morbidity prediction in their model. POMS is one of the only validated measures of short-term morbidity, and allows for a binary outcome to be modelled (presence or absence of morbidity). 11 It is a highly sensitive measure and detects associated morbidity of a magnitude that requires the patient to remain in hospital. POMS criteria are prescriptive and have previously been shown to have very high inter-rater agreement. 12 However, POMS domains include some relatively minor morbidity (such as the presence of a urinary catheter), which, particularly in the first few days after surgery, may be indicative of normal processes and pathways after major surgery rather than reflecting the occurrence of complications. In our study population, the median LOS was 6 days, suggesting that any morbidity observed after this time point may be as a consequence of morbidity leading to a deviation from the usual patient pathway. Previous research has shown the presence of prolonged POMS-defined morbidity to be correlated with poorer long-term outcomes. 14 We propose that POMS offers a more reliable and repeatable means of measuring morbidity than the original Copeland criteria, and one that is suitable for the modern-day evaluation of postoperative outcomes for the purposes of quality improvement and comparative audit. However, we acknowledge that POMS at day 7 or 8 might be perceived as being too sensitive an Table 4 Shrinkage factors to be applied to SORT-morbidity formula in order to improve the accuracy for predicting alternative morbidity outcomes. AUROCs for the recalibrated formulae are also displayed. An example of how to use the shrinkage factors: if applying the SORT-morbidity formula yields a probability (p) of having POMS-defined morbidity on day 7 or 8 of 50%, then logit(p)¼0, and logit[P(Y)] ¼ À1.478 þ 0.894(0), where P(Y) is the probability of having POMS-defined morbidity on day 14 
Our results in relationship to existing literature
In the original SORT development study by Protopapa and colleagues, 7 SORT performance was compared against ASA PS and a modified version of SRS, and was found to be more accurate than either of the comparators. Marufu and colleagues 9 recently reported an AUROC of 0.70 when validating SORT against an emergency hip fracture population. They compared SORT in their study against the Nottingham Hip Fracture Score (NHFS), which showed equivalent discrimination but better calibration. This suggests that SORT is better used as a risk stratification tool for heterogeneous surgical patient groups, and that other tools might be more appropriate for more homogeneous or surgery-specific case-mixes. 30 
Clinical implications
P-POSSUM and POSSUM are the most frequently and widely validated risk stratification models for heterogeneous populations in the literature. 1 They therefore have widespread familiarity amongst anaesthetists and surgeons internationally. However, their value in preoperative prognostication is reduced by the following three factors: firstly, the large number (18) of variables required by their models; secondly, a number of their required variables are available only after surgery; and thirdly, some of the predictor variables are blood test results, which not all patients may have available before surgery. 1 7 SORT and SORT-morbidity are both more parsimonious models compared with P-POSSUM and POSSUM, requiring fewer data items to make a morbidity prediction than POSSUM. Furthermore, SORT and SORT-morbidity require only preoperative data variables in order to make risk predictions for mortality and morbidity, respectively, and in particular, variables which are all known at the time of preoperative assessment in the outpatient clinic, when laboratory variables may not yet be available. These factors therefore make them simpler and more practical to use for preoperative morbidity risk prediction than POSSUM. Risk stratification tools may be more likely to be adopted if they are simple, and when the performance of two or more models is similar, the simplest (most parsimonious) model would be preferable for clinical use.
SORT has been made available for bedside use as an online risk prediction calculator accessible via an internet browser and, more recently, via smartphone applications developed for both iOS and Android devices.
31 32 Although SORT-morbidity differs from SORT in how some of the data variables are used in the model [for example, SORT-morbidity uses ASA PS as a categorical variable with four categories (ASA I, ASA II, ASA III, or ASA !IV) as opposed to three categories as in the original SORT model (ASA I-II, ASA III, or ASA !IV)], it does not require any new data to be collected. It would therefore be straightforward to incorporate the new SORT-morbidity prediction model into these electronic tools, and they can easily be used at the bedside in conjunction with careful clinical assessment to support decisionmaking and promote informed patient consent before surgery. SORT-morbidity, when used together with linear shrinkage factors, therefore provides a potentially powerful tool for perioperative shared decision-making by predicting the risk of developing a range of postoperative morbidity outcomes, over a number of time points.
There is much added benefit in being able to predict morbidity rather than merely mortality, from both an institutional-level perspective and a patient-level perspective. At the institutional level, hospital resource utilization increases with increased patient morbidity after surgery. The ability to predict accurately those patients who might experience prolonged lengths of stay and more interventions as a result of complications allows for better planning and resource allocation. At the patient level, morbidity risk prediction allows for more informed discussions between patients and clinicians when deciding to undergo surgery. During these discussions, the risk of suffering morbidity and mortality can thus be weighed up better against the potential benefit of surgery in improving quality and duration of life.
Unanswered questions and future research
External validation of the new SORT-morbidity model is needed to assess its generalizability in other patient populations. There would also be scope in refitting the SORT-morbidity model to include surgical urgency as a predictor variable. SORT-morbidity could also be recalibrated to predict morbidity outcomes according to other definition systems, such as the Clavien-Dindo classification of surgical complications, which produces an ordinal outcome variable, ranging from Grade 1 (least severe complications) to Grade 5 (most severe). 23 24 In the future, consistent measurement of postoperative morbidity and mortality outcomes and comparing performance between institutions is likely to be increasingly important as health-care costs increase with an ageing population. SORT and SORT-morbidity can therefore be used together for local departmental audits of practice to assess how well patients recover from surgery against predicted mortality and morbidity. They would also have value in case-mix risk adjustment and benchmarking in national registries for tracking institutional quality and perioperative outcomes. Examples of such registries include the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) in the USA, and the Perioperative Quality Improvement Programme (PQIP) currently under development in the UK. 33 34 Both tools would need periodic recalibration when used within such contexts to ensure that they remain valid for surgical populations over time.
Conclusion
We show that SORT-morbidity can be used before surgery to predict postoperative morbidity risk. Risk stratification tools offer clinicians a means of providing more accurate information to patients, help to guide perioperative care decisions, and allow for case-mix adjustments between institutions for audit and research purposes. As mobile digital devices become more widely available, accurate, simple, and parsimonious risk stratification tools, such as SORT and SORT-morbidity, will become increasingly accessible to clinicians for use at the bedside. 
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